148 related articles for article (PubMed ID: 20595378)
21. Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins.
Shen H; Yao M; Sinz M; Marathe P; Rodrigues AD; Zhu M
Mol Pharm; 2019 Sep; 16(9):4065-4076. PubMed ID: 31335150
[TBL] [Abstract][Full Text] [Related]
22. Model analysis of the concentration-dependent permeability of P-gp substrates.
Tachibana T; Kitamura S; Kato M; Mitsui T; Shirasaka Y; Yamashita S; Sugiyama Y
Pharm Res; 2010 Mar; 27(3):442-6. PubMed ID: 20135207
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic assessment of absorptive interaction of oral etoposide and morphine in rats.
Miyazaki M; Nishimura C; Minamida M; Iwanaga K; Kakemi M
Biol Pharm Bull; 2014; 37(3):371-7. PubMed ID: 24351551
[TBL] [Abstract][Full Text] [Related]
24. Impact of P-glycoprotein on blood-retinal barrier permeability: comparison of blood-aqueous humor and blood-brain barrier using mdr1a knockout rats.
Fujii S; Setoguchi C; Kawazu K; Hosoya K
Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4650-8. PubMed ID: 24985475
[TBL] [Abstract][Full Text] [Related]
25. Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers.
Kim TE; Lee H; Lim KS; Lee S; Yoon SH; Park KM; Han H; Shin SG; Jang IJ; Yu KS; Cho JY
Br J Clin Pharmacol; 2014 Sep; 78(3):556-64. PubMed ID: 24602137
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.
O'Brien FE; Clarke G; Fitzgerald P; Dinan TG; Griffin BT; Cryan JF
Br J Pharmacol; 2012 Jun; 166(4):1333-43. PubMed ID: 22250926
[TBL] [Abstract][Full Text] [Related]
27. Ocular pharmacokinetics profile of different indomethacin topical formulations.
Bucolo C; Melilli B; Piazza C; Zurria M; Drago F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858
[TBL] [Abstract][Full Text] [Related]
28. Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.
Kwatra D; Vadlapatla RK; Vadlapudi AD; Pal D; Mitra AK
Int J Pharm; 2010 Aug; 395(1-2):114-21. PubMed ID: 20573570
[TBL] [Abstract][Full Text] [Related]
29. Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats.
Bors LA; Bajza Á; Mándoki M; Tasi BJ; Cserey G; Imre T; Szabó P; Erdő F
Brain Res Bull; 2020 Jul; 160():65-73. PubMed ID: 32344126
[TBL] [Abstract][Full Text] [Related]
30. The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
Li M; de Graaf IA; van de Steeg E; de Jager MH; Groothuis GM
Toxicol In Vitro; 2017 Apr; 40():26-33. PubMed ID: 27939799
[TBL] [Abstract][Full Text] [Related]
31. Impact of the changes in P-glycoprotein activity on domperidone pharmacokinetics in rat plasma.
Bamburowicz-Klimkowska M; Zywiec K; Potentas A; Szutowski M
Pharmacol Rep; 2007; 59(6):752-6. PubMed ID: 18195466
[TBL] [Abstract][Full Text] [Related]
32. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.
Dahan A; Amidon GL
Pharm Res; 2009 Apr; 26(4):883-92. PubMed ID: 19048359
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate.
Eyal S; Chung FS; Muzi M; Link JM; Mankoff DA; Kaddoumi A; O'Sullivan F; Hebert MF; Unadkat JD
J Nucl Med; 2009 May; 50(5):798-806. PubMed ID: 19403878
[TBL] [Abstract][Full Text] [Related]
34. Effect of oral activated charcoal on the pharmacokinetics of quinidine and quinine administered intravenously to rabbits.
Hasan MM; Hassan MA; Rawashdeh NM
Pharmacol Toxicol; 1990 Jul; 67(1):73-6. PubMed ID: 2395819
[TBL] [Abstract][Full Text] [Related]
35. The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study.
Hunt TL; Tzanis E; Bai S; Manley A; Chitra S; McGovern PC
Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):85-92. PubMed ID: 33180250
[TBL] [Abstract][Full Text] [Related]
36. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
Zong J; Pollack GM
J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment.
Buitrago E; Höcht C; Chantada G; Fandiño A; Navo E; Abramson DH; Schaiquevich P; Bramuglia GF
Exp Eye Res; 2010 Jul; 91(1):9-14. PubMed ID: 20307538
[TBL] [Abstract][Full Text] [Related]
38. A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function.
Parasrampuria DA; Lantz MV; Benet LZ
Pharm Res; 2001 Jan; 18(1):39-44. PubMed ID: 11336351
[TBL] [Abstract][Full Text] [Related]
39. Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis.
Macha S; Duvvuri S; Mitra AK
Curr Eye Res; 2004 Feb; 28(2):77-84. PubMed ID: 14972713
[TBL] [Abstract][Full Text] [Related]
40. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
